Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain

PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 30, 2005

Primary Completion Date

June 30, 2007

Conditions
Kidney CancerMetastatic Cancer
Interventions
DRUG

sorafenib tosylate

Trial Locations (12)

46601

CCOP - Northern Indiana CR Consortium, South Bend

49085

Oncology Care Associates, PLLC, Saint Joseph

53226

Medical College of Wisconsin Cancer Center, Milwaukee

60153

Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood

60426

Ingalls Cancer Care Center at Ingalls Memorial Hospital, Harvey

62526

Decatur Memorial Hospital Cancer Care Institute, Decatur

62701

Central Illinois Hematology Oncology Center, Springfield

63141

David C. Pratt Cancer Center at St. John's Mercy, St Louis

60637-1470

University of Chicago Cancer Research Center, Chicago

60201-1781

Evanston Northwestern Health Care - Evanston Hospital, Evanston

61615-7828

Oncology Hematology Associates of Central Illinois, PC - Peoria, Peoria

46885-5099

Fort Wayne Medical Oncology and Hematology, Fort Wayne

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00301847 - Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain | Biotech Hunter | Biotech Hunter